DSG‑PEG, MW 550
DSG‑PEG, MW 550 (full name: 1,2‑distearoyl‑sn‑glycerol‑PEG550 / distearoyl‑rac‑glycerol‑PEG550) is an amphiphilic PEG‑lipid conjugate formed by covalently linking 1,2‑distearoyl‑sn‑glycerol (DSG) with a polyethylene glycol (PEG) chain of average molecular weight ~550 Da.
Core Structure & Properties
- Amphiphilic design:
- Hydrophobic domain: Two saturated C18:0 stearoyl chains on a glycerol backbone (DSG), acting as a membrane anchor.
- Hydrophilic domain: Short PEG‑550 chain (typically methoxy‑terminated, mPEG‑DSG) providing water solubility and steric stabilization.
- Physical form: White to off‑white solid/powder.
- Solubility: Soluble in DMSO, DCM, DMF, ethanol, chloroform, THF; good aqueous dispersibility.
- Purity: Typically ≥90% (analytical grade).
- Storage: −20 °C, desiccated; stable under neutral conditions.
Key Functions
- Lipid nanoparticle (LNP) / liposome PEGylation
- Inserts into lipid bilayers via the DSG anchor; the PEG chain forms a hydration layer on the particle surface.
- Reduces non‑specific protein adsorption and immune recognition, prolonging in vivo circulation time.
- Improves colloidal stability and prevents aggregation.
- Controlled release & formulation tuning
- Short PEG‑550 balances hydrophilicity/lipophilicity for rapid‑release or fast‑clearance delivery systems.
- Compatible with cationic lipids for nucleic acid (mRNA, siRNA, plasmid DNA) delivery.
- Surface functionalization
- Serves as a building block for targeted carriers; end‑functionalized variants (e.g., DSG‑PEG550‑NH₂, ‐COOH) enable conjugation to antibodies, peptides, or ligands.
Main Applications
- Drug delivery: Formulation of LNPs, liposomes, and micelles for small‑molecule drugs, proteins, and nucleic acids.
- Gene therapy: Non‑viral vector stabilization and transfection enhancement.
- Biomedical research: Surface modification of nanocarriers, in vitro/in vivo delivery studies.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
